eprosartan

Drug Interactions Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Do not co-administer aliskiren with eprosartan in patients with diabetes. Avoid use of aliskiren with eprosartan in patients with renal impairment (GFR < 60 mL/min).

Mechanism: Both drugs work on the same system to lower blood pressure, which can cause blood pressure to drop too low or harm the kidneys.

What to do: Do not use these drugs together if you have diabetes, and avoid this combination if you have kidney problems.

or 800 mg q.d.) doses have been safely used concomitantly with a thiazide diuretic (hydrochlorothiazide).

Mechanism: These two drugs work together to lower blood pressure and have been shown to be safe when used at the same time.

What to do: No special changes are usually needed, but you should still follow your doctor's instructions for blood pressure monitoring.

Concomitant administration of eprosartan and warfarin had no effect on steady-state prothrombin time ratios (INR) in healthy volunteers. Eprosartan has been shown to have no effect on the pharmacokinetics of digoxin and the pharmacodynamics of warfarin and glyburide.

Mechanism: Eprosartan does not change how warfarin works or how it affects your blood's ability to clot.

What to do: You can typically take these medications together without needing to adjust your warfarin dose.

have been safely used concomitantly with sustained-release calcium channel blockers (sustained-release nifedipine) with no clinically significant adverse interactions.

Mechanism: These two blood pressure medicines do not have a negative effect on each other when taken together.

What to do: You can safely take these medications together as prescribed by your doctor.

Eprosartan is not metabolized by the cytochrome P450 system; eprosartan steady-state concentrations were not affected by concomitant administration of ketoconazole or fluconazole, potent inhibitors of CYP3A and 2C9, respectively. Because eprosartan is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and ketoconazole and fluconazole, potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on eprosartan pharmacokinetics.

Mechanism: Ketoconazole blocks certain liver proteins, but eprosartan is not processed by those proteins, so its levels do not change.

What to do: No special precautions are needed when taking these two drugs together.